TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cervical cancer screening behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Centre of Pressure Length of Trace
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV remodeling (increase of LV end-diastolic volume > 15%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of intraoperative complication
Endpoint domain: Adverse events/effects
Primary endpoint: rate of 30 day morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in Disease Activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative number of SARS-COV-2 infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Minimum Audible Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to perform a simulated interscalene block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: parathyroid hormone gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Type and amount of bacterial growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Post surgery infections
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics and pharmacodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in colonic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cardiovascular diseases
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive disorder
Endpoint domain: Mortality/survival
Primary endpoint: Change in DEXA-measured Limb Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of medically attended health outcomes related to influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieving a TNA Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Parasite Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-day Cure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of eye fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Profile (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Profile Extrapolated to Infinite Time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasticity of cortical and corticospinal neuronal circuits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasticity of spinal neuronal circuits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Freedom from XFINE lead-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Electrical performances confirmation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pain score 48 hours following surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC [0-t]) for Cefixime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for Cefixime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced at Least One Adverse Event (AE) or One Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Capacity to detect VCA IgM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete Clearance Rate - Percentage of Participants With Treatment Success (PP Population)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Clearance Rate - Percentage of Participants With Treatment Success (ITT Population)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure
Endpoint domain: Adverse events/effects
Primary endpoint: FMRI response in face recognition task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in Hamilton Depression Rating Scale (HAMD)-17
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of EUS and CT scan for liver carcinoma detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Systemic insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breathing vigor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in blood hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Eczema Area and Severity Index (EASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Assay of DNA and RNA markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Urinary Tract Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Infants With Major Congenital Malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functionality and disability of the paretic hemibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independency of patient with hemiparesis
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Realization of fine clamp of the plegia hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical deterioration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Language Development: Vocabulary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Executive Function & Behavioral Regulation: Executive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Socio-Emotional Processing: Behavior/Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cannabis-related problems
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in intracerebral levels of vascular endothelial growth factor (VEGF), interleukin-1ß (IL-1ß), and other cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in gene expression after burn injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and type of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Nipple Projection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of bowel evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to bowel evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stool Quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in Disease Activity Score (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcium absorption efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: C-LVEDP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) for Tadalafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration (Cp12h) for Tadalafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Plasma Concentration-time Curve (AUC0-72h) for Tadalafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ for Tadalafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean tube extrusion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lower Extremity Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Implementation outcome score
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: PROMIS Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS Physical Function CAT
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fraction of Patients with sdAb Generated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Paraprotein-targeting sdAbs Generated Per Patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced pregnancy-related weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global [11C]HED Retention Index (RI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the First Occurrence of Composite Cardiovascular Events
Endpoint domain: Mortality/survival
Primary endpoint: Knee joint pain during knee extensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Dose-Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: vital organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with failure of initial intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Histological Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endotracheal tube resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in pain as measured by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Acetylsalicylic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of Acetylsalicylic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion Weighted Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative dose of heparin anticoagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ki67
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Theta cordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurocognitive status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subject satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subject anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Confirmed MDD Symptoms by SAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the sum of T1 Gd-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: 400 meter walk time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Interstitial fluid pressure (IFP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peritoneal recurrence free survival
Endpoint domain: Mortality/survival
Primary endpoint: TIME(T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: c(MAX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical status Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Death and/or ESRD
Endpoint domain: Mortality/survival
Primary endpoint: Surgeon's attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of AZD5363
Endpoint domain: Adverse events/effects
Primary endpoint: Dose limited toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in mean number of micturitions per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Presence of Aspergillus in sputum or respiratory samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall response rate (complete response, partial response, or stable disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lab abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Achieved Complete and Partial Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forearm Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dental Caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital Length of stay (LOS)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Maximum procedural pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate - 50 Percent or Greater Reduction in PHQ-9 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of insomnia symptoms
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: SVR-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6 Minute Walk Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: collagen 1 fraction indicator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: collagen 2 fraction indicator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of open water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of water related
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of total water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum denaturation temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: collagen denaturation enthalpy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Adherence MPR
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medication Adherence PDC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Autism Treatment Evaluation Checklist scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success/favorable clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Systematic Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency/severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: PARS Behavior Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PARS Suicide Knowledge Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PARS Attitude Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: All adverse events up to the end of study
Endpoint domain: Adverse events/effects
Primary endpoint: Survival status at end of study
Endpoint domain: Mortality/survival
Primary endpoint: Serum antibodies to Interferon gamma-1b after the last injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fluid change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: genomic expression profiles of reduced scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Treatment response measured by QIDS-SR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of TcB compared to TSB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tensile Strength of White Adipose Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary and aortic calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Carotid plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blastocyst outcome prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total dose of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum nerve growth factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUC by Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration After Each Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half Life for Each Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Quantities of sunscreen applied
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose adjustment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Severity of Post-operative Respiratory Compromise Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Histologically confirmed greater than or equal to CIN3 detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nasal colonization with Staphylococcus aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Visual Functional Quality Scale (VFQ-25)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: General Anxiety Disorder Scale (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Low-density Lipoprotein (LDL) Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients Having Attenuation of Accelerated Telomere Attrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distress due to breathlessness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of hemarthrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: WHO Toxicity scale
Endpoint domain: Adverse events/effects
Primary endpoint: Embryo Implantation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: UCLA Shoulder Score Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patients' compliance to the program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Physical condition of the patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological condition of the patients (PHQ8)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychological condition of the patients (GAD7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse Events Graded According to NCI CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Achieving Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Preference for medical care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of irritable bowel syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Endothelial progenitor cell number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skeletal muscle capillarization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Willingness to come forward for HIV and STI evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nocturnal parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean COP velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with mTBI
Endpoint domain: Mortality/survival
Primary endpoint: Adverse effect on growth of uropathogens
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 2 or Greater Adverse Events Related to Study Drugs
Endpoint domain: Adverse events/effects